VEDOLIZUMAB INJ,SOLN
Clinical Criteria Summary
Inclusion Criteria
- Had a clinical response after Week 6 following vedolizumab intravenous induction doses at Weeks 0 and 2
- OR is receiving intravenous doses of vedolizumab to maintain clinical remission
Clinical Response Definitions
- Ulcerative Colitis: Reduction in total Mayo score of ≥ 3 points and ≥ 30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1.
- Crohn's Disease: ≥ 70-point decrease in Crohn's Disease Activity Index (CDAI) score from baseline.